Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Inclusion Criteria:

* Histologically confirmed B-cell lymphomas, excluding CLL (Chronic Lymphocytic Leukemia), that is recurrent or refractory after at least one prior therapy and for which no other potentially curative therapy is available.
* Age ≥ 18 years
* ECOG Performance Status (PS) ≤ 2
* Laboratory parameters

  * if SLL, lymphocyte count \< 5,000/µL
  * Absolute neutrophil count ≥ 1000/µL
  * Platelets ≥ 75,000/µL
  * Creatinine ≤ 1.5x upper limit of normal or calculated creatinine clearance \> 40mL/min
  * AST, ALT ≤ 2.5 x upper limit of normal (ULN)
  * Bilirubin ≤ 2.0 mg/mL
  * Serum potassium ≥ 3.5 mEq/L and serum magnesium ≥ 1.7 mEq/dL (electrolytes may be corrected with supplementation).
  * PT \< 1.5 x ULN and PTT \< 1.2 x ULN (unless receiving therapeutic anticoagulation).
* Patient is, in investigator's opinion, willing and able to comply with the protocol requirements and offers written informed consent.
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control ( i.e., oral injectable hormonal methods; barrier methods such as intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence)for the duration of the study.
* Male subject agrees to use an acceptable method for contraception for the duration of study.

Exclusion Criteria:

* History of brain metastasis including leptomeningeal metastasis.
* Chemotherapy of radiotherapy within 3 weeks prior to entering the study.
* Prior histone deacetylase inhibitor as cancer treatment.
* Concurrent treatment with other investigational agents or cancer treatment.
* Unable to take oral medications.
* Active ischemic heart disease or congestive heart failure. If there is suspicion of cardiac disease, left ventricular ejection fraction (LVEF) must be ≥ 45%, otherwise study to evaluate EF is not required.
* Persistent blood pressure (BP) of ≥ 160/95 (three separate readings on different days).
* History of allergic reactions attributed to compounds of similar chemical or biological composition to carfilzomib and vorinostat.
* Known clinical significant infection including infection with human immunodeficiency virus (HIV), or active hepatitis B or C, requiring treatment.
* Serious medical or psychiatric illness likely to interfere with patient participation.
* Pregnant or nursing. Confirmation that a woman is not pregnant must be established by a negative serum pregnancy test result obtained at screening.
* Pregnancy testing is not required for post-menopausal or surgically sterilized women.
* No prior allogeneic stem cell transplant.
* Patients scheduled for any type of stem cell transplant within 4 weeks of treatment.
* Patients who have valproic acid for epilepsy can enroll, provided that they stopped drug at least 30 days prior to enrollment and they will be on a stable, effective dose of an alternative anti-seizure medication.